Goding group | Cell fate switching
Professor Colin Goding
Our interests lie in understanding how phenotypic heterogeneity is generated within cancer, and the molecular mechanisms that drive three major barriers to effective therapy: microenvironment-driven metastatic spread, dormancy, and phenotypic drug-resistance. Our long-term aim is to develop effective therapies for cancer that take phenotypic heterogeneity into account.
Primarily using melanoma as a model, our work is focussed on the complex interplay between signalling and transcription that underpins the gene expression programs to determine specific cell identities. We use molecular and cellular biology, as well as genome-wide approaches and bioinformatics to address these key issues through a highly collaborative research program that engages with many other laboratories within Oxford and worldwide.
Our team
-
Colin Goding
Professor of Oncology
-
Pakavarin Louphrasitthiphol
Post-doctoral Fellow
-
Sarah Andrews
DPhil student
Latest Goding group news
Selected publications
-
TPC1 regulates melanoma tumourigenesis via mTORC1 and TFEB.
Jin X. et al, (2024), Heliyon, 10
-
The Lipid Droplet Protein DHRS3 Is a Regulator of Melanoma Cell State
Johns E. et al, (2024), Pigment Cell & Melanoma Research
-
A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Bleloch JS. et al, (2024), Cancer medicine, 13